Search

Displaying results 7791 - 7800 of 8468 in total
  1. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.

  2. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853].

  3. Drug

    GC5107

    go.drugbank.com/drugs/DB17604
    Investigational

    It is marketed as IVIG-SN.

  4. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    It was generated by HGS using the Abgenix XenoMouse technology.

  5. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.

  6. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]

  7. Drug

    Zibrofusidic acid

    go.drugbank.com/drugs/DB20799
    Investigational

    Zibrofusidic acid has a monoisotopic molecular weight of 594.26 Da.

  8. Drug

    Evixapodlin

    go.drugbank.com/drugs/DB21520
    Investigational

    Evixapodlin has a monoisotopic molecular weight of 690.22 Da.

  9. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  10. Drug

    Atl146e

    go.drugbank.com/drugs/DB05191
    Investigational

    ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.